Can Hormone Therapy Start During Perimenopause?

What Perimenopause Actually Is (and Why It Matters for HT Timing)

Perimenopause is the transition window between regular reproductive cycles and menopause, defined retrospectively after 12 consecutive months without a period. Most women enter perimenopause between ages 40 and 44, though some begin as early as their late 30s. The transition lasts a median of 4 to 8 years according to the Study of Women's Health Across the Nation (SWAN) [1].

During this phase, estradiol levels fluctuate wildly rather than declining in a straight line. A single blood draw may show estradiol at 200 pg/mL one week and 30 pg/mL the next. These erratic swings drive the hallmark symptoms: hot flashes, sleep fragmentation, mood instability, and irregular bleeding. The Stages of Reproductive Aging Workshop (STRAW+10) criteria classify perimenopause into early and late stages based on cycle-length variability and FSH levels (Harlow et al., 2012) [2]. Late-stage perimenopause, characterized by skipped cycles of 60 days or longer, is when symptoms typically peak.

This matters for treatment timing because the physiological window in which HT confers its greatest benefit, often called the "window of opportunity," opens during perimenopause, not after the final period. Waiting until a woman is fully postmenopausal means she may endure years of preventable symptoms.

Guidelines That Support Starting HT During Perimenopause

Every major menopause-focused medical society endorses HT initiation for symptomatic perimenopausal women. The North American Menopause Society (NAMS) 2022 position statement explicitly recommends HT for women experiencing bothersome vasomotor symptoms during the menopausal transition, provided no contraindications exist (NAMS 2022 Position Statement) [3]. The Endocrine Society's 2015 clinical practice guideline similarly supports HT for symptomatic women within 10 years of menopause onset or before age 60 (Stuenkel et al., 2015) [4].

The International Menopause Society (IMS) goes further: their 2016 recommendations note that HT initiated in early perimenopause may offer a "window of opportunity" for cardiovascular protection that closes when therapy is started years after menopause (Baber et al., 2016) [5].

This consensus is not new. It reflects a correction after the initial 2002 Women's Health Initiative (WHI) findings, which enrolled women with a mean age of 63, well past the perimenopausal window. Later age-stratified reanalysis of the WHI showed that women who started conjugated equine estrogen (CEE) at ages 50 to 59 had a trend toward reduced coronary heart disease events and significantly lower all-cause mortality compared with placebo (Manson et al., 2013) [6].

The Timing Hypothesis: Why Earlier Is Often Better

The "timing hypothesis" (also called the "critical window hypothesis") proposes that estrogen therapy protects the cardiovascular system only when initiated while arteries remain relatively healthy. The ELITE trial (Early versus Late Intervention Trial with Estradiol) tested this directly. Women randomized to oral 17β-estradiol within 6 years of menopause showed significantly less progression of carotid intima-media thickness (CIMT) over 5 years than those who received placebo. Women who started estradiol 10 or more years after menopause showed no such benefit (Hodis et al., 2016) [7].

The Danish Osteoporosis Prevention Study (DOPS) reinforced this finding with hard clinical endpoints. Women randomized to HT shortly after menopause (mean age 50) and followed for 16 years had a significantly lower composite risk of death, heart failure, and myocardial infarction compared with controls (HR 0.61 to 95% CI 0.39 to 0.94) (Schierbeck et al., 2012) [8]. That hazard ratio represents a 39% relative risk reduction.

These data do not mean HT is a cardiac drug. They mean the timing of initiation shapes the risk-benefit profile. Starting during perimenopause places a woman squarely within the favorable window.

Which Hormones Are Used During Perimenopause?

The formulation choice depends on whether a woman has an intact uterus, her symptom profile, and her risk factors.

Estrogen options. Transdermal 17β-estradiol (patches delivering 0.025 to 0.1 mg/day, or gels) is generally preferred over oral estrogen during perimenopause. The ESTHER study showed that transdermal estradiol did not increase venous thromboembolism (VTE) risk, while oral estrogen raised VTE risk approximately two- to fourfold (Canonico et al., 2007) [9]. For women with migraine with aura, obesity (BMI ≥30), or elevated thrombotic risk, transdermal delivery is the standard of care.

Progestogen requirement. Any woman with an intact uterus who receives systemic estrogen must also receive a progestogen to prevent endometrial hyperplasia. Options include oral micronized progesterone (100 to 200 mg nightly), the levonorgestrel-releasing intrauterine system (LNG-IUS, 52 mg), or cyclic medroxyprogesterone acetate (MPA 5 to 10 mg for 12 to 14 days per month). The PEPI trial demonstrated that micronized progesterone preserved the favorable HDL effects of estrogen better than MPA (The Writing Group for the PEPI Trial, 1995) [10].

Cyclic vs. continuous regimens. During perimenopause, cyclic combined therapy (estrogen daily plus progestogen for 12 to 14 days per cycle) produces a predictable withdrawal bleed and is better tolerated than continuous combined therapy, which often causes irregular breakthrough bleeding in women who are still having some spontaneous periods. After 12 months of amenorrhea, the regimen can be converted to continuous combined.

Oral contraceptives as an alternative. Low-dose combined oral contraceptives (20 to 35 mcg ethinyl estradiol) offer both symptom control and contraception. The American College of Obstetricians and Gynecologists (ACOG) states that healthy, nonsmoking perimenopausal women can use low-dose pills until menopause (ACOG Practice Bulletin No. 141) [11]. This approach provides higher estrogen doses than standard HT, which can better suppress erratic ovarian activity.

Symptom Relief: What the Evidence Shows

The primary indication for HT in perimenopause is vasomotor symptom (VMS) management. Hot flashes affect up to 80% of women during the menopausal transition, and moderate-to-severe VMS impair sleep quality, work productivity, and overall life satisfaction.

A Cochrane review of 24 randomized trials (N=3,329) found that oral or transdermal estrogen therapy reduced hot flash frequency by 75% and hot flash severity by 87% compared with placebo (MacLennan et al., 2004) [12]. No non-hormonal alternative has matched these effect sizes. For context, the SSRI paroxetine (Brisdelle, 7.5 mg), the only FDA-approved non-hormonal VMS treatment at its original dose, reduced hot flash frequency by approximately 33% in its key trial.

Beyond hot flashes, HT during perimenopause addresses several other estrogen-withdrawal symptoms:

• Sleep disturbance. Estrogen therapy improves self-reported sleep quality, and progesterone has mild sedative properties via its GABAergic metabolite allopregnanolone. Women on micronized progesterone 300 mg at bedtime showed improved sleep architecture in polysomnographic studies (Schüssler et al., 2008) [13].
• Mood symptoms. The Kronos Early Estrogen Prevention Study (KEEPS) found that transdermal estradiol improved mood and reduced depressive symptoms in recently menopausal women compared with placebo, though the effect was most pronounced in women with elevated baseline depressive symptoms (Gleason et al., 2015) [14].
• Vaginal dryness and dyspareunia. Systemic estrogen restores vaginal epithelial thickness and lubrication. For women whose primary complaint is genitourinary, low-dose vaginal estrogen (cream, ring, or tablet) is effective and carries minimal systemic absorption.
• Joint aches. The WHI observed a significant reduction in joint pain and stiffness among women randomized to CEE versus placebo.

Bone Health: Building the Case for Early Initiation

Bone loss accelerates during the perimenopausal transition, with women losing 1% to 2% of lumbar spine bone mineral density (BMD) per year in the 2 to 3 years flanking the final menstrual period. Data from SWAN showed that the rate of bone loss was greatest during late perimenopause and the first 2 postmenopausal years, then decelerated (Greendale et al., 2012) [15].

Starting HT during this rapid-loss phase can blunt or prevent the decline. The DOPS trial showed that women who began HT at a mean age of 50 maintained lumbar spine BMD that was 5.1% higher than untreated controls after 10 years [8]. The WHI estrogen-alone arm (CEE 0.625 mg) reduced hip fracture risk by 39% (HR 0.61 to 95% CI 0.41 to 0.91) in the overall cohort. Among women aged 50 to 59, the benefit was consistent (Anderson et al., 2004) [16].

For perimenopausal women who are not yet candidates for bisphosphonates or denosumab but want to protect bone density, HT serves a dual purpose: symptom management and skeletal preservation. The Endocrine Society recognizes HT as a first-line option for fracture prevention in postmenopausal women under 60 and those within 10 years of menopause [4].

Risk Considerations: Breast Cancer, VTE, and Stroke

No discussion of HT timing is complete without an honest accounting of risks. The absolute magnitude of these risks is smaller than many patients and clinicians assume, particularly for women who start during perimenopause.

Breast cancer. The WHI combined estrogen-progestogen arm (CEE+MPA) showed an increased breast cancer risk after approximately 5 years of use: 8 additional cases per 10,000 women-years, or roughly 1 extra case per 1,000 women per year of use. The estrogen-alone arm (for hysterectomized women) showed no increase in breast cancer risk over 7.2 years, and a subsequent 18-year follow-up found a statistically significant decrease in breast cancer incidence and mortality in the CEE-alone group (Chlebowski et al., 2020) [17]. The type of progestogen matters: observational data from the E3N French cohort suggested that micronized progesterone combined with transdermal estradiol did not significantly increase breast cancer risk over 8 years of follow-up, while synthetic progestins did (Fournier et al., 2008) [18].

Venous thromboembolism. Oral estrogen approximately doubles VTE risk. The absolute risk in healthy women aged 50 to 59 remains low (roughly 2 additional events per 10,000 women-years). Transdermal estradiol avoids hepatic first-pass metabolism and does not increase VTE risk in observational studies, including in women with obesity or Factor V Leiden heterozygosity [9].

Stroke. The WHI observed a modest increase in ischemic stroke with oral CEE (6 additional events per 10,000 women-years in the 50-to-59 age group). Transdermal estradiol at standard doses (≤0.05 mg/day) has not been associated with increased stroke risk in large observational analyses (Renoux et al., 2010) [19].

The overall message: for healthy perimenopausal women under 60, the benefits of HT for symptoms and bone typically outweigh the risks, especially when transdermal estradiol and micronized progesterone are used. Absolute contraindications include a history of estrogen-sensitive breast cancer, active liver disease, unexplained vaginal bleeding, and recent VTE or stroke.

Contraception During Perimenopause: A Practical Overlap

A commonly overlooked point: perimenopausal women can still ovulate and conceive. Pregnancy rates in women aged 40 to 44 are low but not zero. Standard menopausal HT doses (0.5 to 1 mg oral estradiol, or 0.025 to 0.05 mg transdermal estradiol) do not suppress ovulation reliably.

Women who need both symptom control and contraception have two main paths. First, low-dose combined oral contraceptives, which suppress ovulation and provide predictable cycles. Second, a progestogen-only method (LNG-IUS, depot medroxyprogesterone, or a progestin-only pill) combined with add-back estrogen for VMS.

ACOG recommends continuing contraception until menopause is confirmed. For women on low-dose pills, one strategy is to stop the pill at age 50 to 55, check FSH after a washout period, and transition to standard HT if the FSH is elevated (≥30 mIU/mL on two draws 6 weeks apart) [11].

How to Start: The Clinical Conversation

Initiating HT during perimenopause does not require complex testing. Diagnosis of perimenopause is clinical: irregular cycles plus symptoms in a woman of appropriate age. FSH testing is generally unreliable because of hormonal fluctuation and adds cost without changing management.

A reasonable starting protocol for a symptomatic perimenopausal woman with an intact uterus:

1. Transdermal estradiol 0.025 to 0.05 mg/day (patch or gel)
2. Micronized progesterone 200 mg orally at bedtime for 12 days per calendar month (cyclic regimen)
3. Re-evaluate at 3 months for symptom response and bleeding pattern
4. Titrate estradiol dose upward if VMS persists (maximum 0.1 mg/day transdermal)
5. Consider switching to continuous combined therapy after 12 months of amenorrhea

Baseline mammography should be current per USPSTF screening guidelines (biennial for average-risk women aged 50 to 74, with shared decision-making for ages 40 to 49). No routine coagulation testing is required unless the patient has a personal or strong family history of VTE.

Duration of therapy is individualized. NAMS advises against arbitrary limits (e.g., "5 years max") and instead recommends periodic reassessment of the benefit-risk balance [3]. For women using HT primarily for VMS, an annual "should I continue?" conversation is appropriate. Some women will taper and stop after 3 to 5 years; others will continue into their 60s based on persistent symptoms and individual risk profiles. The 2022 NAMS statement notes: "There is no mandatory upper time limit for HT use."